Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS Common Stock Issued

Cash raised by issuing new shares.

Viatris Inc.NASDAQ: VTRS

Common Stock Issued · Q2 FY2026 · quarter ended Jun 2026

Common stock issued grows in line with its trailing trend

Q2 FY2026 common stock issued of $700K rose 0.0% year over year, in line with the +0.0% change in trailing-twelve-month common stock issued. Sequentially, it rose 40.0% from the prior quarter. Over 3 fiscal years it compounded at -7.6% a year.

Context

  • Common stock issued amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Common stock issued increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +0.0% holds above the trailing-twelve-month pace of +0.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$700K+40.0% QoQ
Last fiscal yearDec 2025
$2.6M+4.0% YoY
LTMJun 2026
$2.5M+0.0% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year+4.0%——
3-year CAGR-7.6%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
2.6M USD
Year-over-year change
+4.0%

Common Stock Issued vs competitors

How VTRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +0.0% is the 3rd highest of 6, against a peer median of -57.0%.
  • Common stock issued amounts to 0.0% of revenue for VTRS, versus a peer median of 0.0%.
VTRS Competitors
Common Stock Issued for VTRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹426.48M INR+106.3%+4.3%0.1%
ALKSAlkermes plcLTM Sep 2026$11.18M USD-72.4%+30.3%0.6%
VTRSViatris Inc.LTM Jun 2026$2.5M USD+0.0%-7.6%0.0%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$1.98M USD-65.9%—0.3%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$1.67M USD-57.0%—0.2%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$1.29M USD+70.6%—0.0%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$0 USD——0.0%
HLNHaleon plcFY2025£0 GBP——0.0%
OGNOrganon & Co.LTM Sep 2026$0 USD——0.0%
BHCBausch Health Companies Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding VTRS) —-57.0%+17.3%0.0%

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.27B)2.08B54.7M(634.2M)(3.51B)
Depreciation & Amortization4.51B3.03B2.74B2.71B2.8B
Deferred Income Tax675.7M(25.9M)(387.1M)(767.6M)(476.5M)
Stock-Based Compensation111.2M116.4M180.7M146.1M177.7M
Change in Working Capital(1.8B)(922.6M)(711.3M)(318.6M)(2.5B)
Accounts Receivables59.3M(240.3M)78.6M300.1M334.6M
Inventory(427.6M)(259.5M)(613.3M)(723.4M)(106.4M)
Accounts Payables(70.4M)170.2M314.7M36M(168M)
Other Working Capital(1.37B)(593M)(491.3M)68.7M(2.56B)
Other Non-Cash Items797.4M(1.28B)922.1M1.17B5.84B
Operating Cash Flow3.02B3B2.8B2.3B2.32B
Capital Expenditures(509.4M)(489.4M)(474.5M)(326M)(378.8M)
Acquisitions (Net)277M0(667.7M)(350M)0
Purchases of Investments(30.2M)(30.2M)(26.3M)(26M)(23.9M)
Sales of Investments29.8M29.9M26.3M26M23.9M
Other Investing Activities115M1.96B280.6M2.48B(48.9M)
Investing Cash Flow(117.8M)1.47B(764.1M)1.8B(427.7M)
Debt Repayment(2.1B)(3.28B)(1.25B)(3.71B)100K
Common Stock Issued03.3M3.1M2.5M2.6M
Common Stock Repurchased(17.4M)0(250M)(250M)(500.5M)
Dividends Paid(399M)(581.6M)(575.6M)(574.8M)(561.2M)
Other Financing Activities(496.5M)(19.5M)(229.8M)205.6M(234.9M)
Financing Cash Flow(3.01B)(3.88B)(2.3B)(4.33B)(1.29B)
Effect of Forex Changes(30.9M)(38.9M)(2.5M)(30.7M)17.6M
Net Change in Cash(143.8M)556.3M(268.9M)(257.5M)611.9M
Free Cash Flow2.51B2.51B2.33B1.98B1.94B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.